| Product Code: ETC7222006 | Publication Date: Sep 2024 | Updated Date: Aug 2025 | Product Type: Market Research Report | |
| Publisher: 6Wresearch | Author: Vasudha | No. of Pages: 75 | No. of Figures: 35 | No. of Tables: 20 |
1 Executive Summary |
2 Introduction |
2.1 Key Highlights of the Report |
2.2 Report Description |
2.3 Market Scope & Segmentation |
2.4 Research Methodology |
2.5 Assumptions |
3 France Large Molecule Drug Substance CDMO Market Overview |
3.1 France Country Macro Economic Indicators |
3.2 France Large Molecule Drug Substance CDMO Market Revenues & Volume, 2021 & 2031F |
3.3 France Large Molecule Drug Substance CDMO Market - Industry Life Cycle |
3.4 France Large Molecule Drug Substance CDMO Market - Porter's Five Forces |
3.5 France Large Molecule Drug Substance CDMO Market Revenues & Volume Share, By Service, 2021 & 2031F |
3.6 France Large Molecule Drug Substance CDMO Market Revenues & Volume Share, By Source, 2021 & 2031F |
3.7 France Large Molecule Drug Substance CDMO Market Revenues & Volume Share, By End-user, 2021 & 2031F |
4 France Large Molecule Drug Substance CDMO Market Dynamics |
4.1 Impact Analysis |
4.2 Market Drivers |
4.2.1 Increasing demand for biologics and large molecule drugs in the pharmaceutical industry. |
4.2.2 Growing trend of outsourcing drug substance manufacturing to Contract Development and Manufacturing Organizations (CDMOs) for cost-efficiency and expertise. |
4.2.3 Technological advancements in biopharmaceutical manufacturing processes leading to the development of complex large molecule drugs. |
4.3 Market Restraints |
4.3.1 Stringent regulatory requirements and quality standards in the biopharmaceutical industry. |
4.3.2 High initial capital investment and operational costs associated with setting up large molecule drug substance manufacturing facilities. |
5 France Large Molecule Drug Substance CDMO Market Trends |
6 France Large Molecule Drug Substance CDMO Market, By Types |
6.1 France Large Molecule Drug Substance CDMO Market, By Service |
6.1.1 Overview and Analysis |
6.1.2 France Large Molecule Drug Substance CDMO Market Revenues & Volume, By Service, 2021- 2031F |
6.1.3 France Large Molecule Drug Substance CDMO Market Revenues & Volume, By Contract Manufacturing, 2021- 2031F |
6.1.4 France Large Molecule Drug Substance CDMO Market Revenues & Volume, By Clinical, 2021- 2031F |
6.1.5 France Large Molecule Drug Substance CDMO Market Revenues & Volume, By Commercial, 2021- 2031F |
6.1.6 France Large Molecule Drug Substance CDMO Market Revenues & Volume, By Contract Development, 2021- 2031F |
6.1.7 France Large Molecule Drug Substance CDMO Market Revenues & Volume, By Cell Line Development, 2021- 2031F |
6.1.8 France Large Molecule Drug Substance CDMO Market Revenues & Volume, By Process Development, 2021- 2031F |
6.2 France Large Molecule Drug Substance CDMO Market, By Source |
6.2.1 Overview and Analysis |
6.2.2 France Large Molecule Drug Substance CDMO Market Revenues & Volume, By Mammalian, 2021- 2031F |
6.2.3 France Large Molecule Drug Substance CDMO Market Revenues & Volume, By Microbial, 2021- 2031F |
6.2.4 France Large Molecule Drug Substance CDMO Market Revenues & Volume, By Others, 2021- 2031F |
6.3 France Large Molecule Drug Substance CDMO Market, By End-user |
6.3.1 Overview and Analysis |
6.3.2 France Large Molecule Drug Substance CDMO Market Revenues & Volume, By Biotech Companies, 2021- 2031F |
6.3.3 France Large Molecule Drug Substance CDMO Market Revenues & Volume, By CRO, 2021- 2031F |
6.3.4 France Large Molecule Drug Substance CDMO Market Revenues & Volume, By Others, 2021- 2031F |
7 France Large Molecule Drug Substance CDMO Market Import-Export Trade Statistics |
7.1 France Large Molecule Drug Substance CDMO Market Export to Major Countries |
7.2 France Large Molecule Drug Substance CDMO Market Imports from Major Countries |
8 France Large Molecule Drug Substance CDMO Market Key Performance Indicators |
8.1 Manufacturing capacity utilization rate. |
8.2 Percentage of repeat business from existing clients. |
8.3 Number of successful technology transfers with minimal downtime. |
8.4 Average project turnaround time. |
8.5 Employee training hours dedicated to new technologies and processes. |
9 France Large Molecule Drug Substance CDMO Market - Opportunity Assessment |
9.1 France Large Molecule Drug Substance CDMO Market Opportunity Assessment, By Service, 2021 & 2031F |
9.2 France Large Molecule Drug Substance CDMO Market Opportunity Assessment, By Source, 2021 & 2031F |
9.3 France Large Molecule Drug Substance CDMO Market Opportunity Assessment, By End-user, 2021 & 2031F |
10 France Large Molecule Drug Substance CDMO Market - Competitive Landscape |
10.1 France Large Molecule Drug Substance CDMO Market Revenue Share, By Companies, 2024 |
10.2 France Large Molecule Drug Substance CDMO Market Competitive Benchmarking, By Operating and Technical Parameters |
11 Company Profiles |
12 Recommendations |
13 Disclaimer |